Trial Profile
Phase II study of Carboplatin plus nab-Paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2020
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Interstitial lung diseases; Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Dec 2019 Results published in the Cancer Science
- 31 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2014 Status changed from not yet recruiting to recruiting as reported by UMIN record.